Abstract
Molina Healthcare will report fiscal second-quarter 2026 results on July 22, 2026 Post-Mkt; this preview summarizes consensus expectations and company guidance on revenue, margins, net income, and adjusted EPS, highlights main business dynamics and segment trends, and compiles prevailing institutional views through July 15, 2026.
Market Forecast
Consensus modeled for the current quarter points to revenue of 10.78 billion US dollars, down 1.56% year over year, with EBIT near 0.14 billion US dollars and EPS around 1.39; forecasts imply significant year-over-year pressure on adjusted EPS of about 75.98% and EBIT of about 67.52%. Margin modeling suggests muted profitability, with the recent trend in gross margin and net margin leaving limited room for near-term expansion; specific company projections for gross margin and net margin this quarter are not disclosed in the dataset.
Across the core operations, premiums remain the dominant revenue driver with an estimated mix above 94%, while investment income provides a modest offset during periods of medical cost variability. Medicaid-centered contracts continue to define scale, with membership churn, redeterminations, and medical cost trends as the primary moving parts.
The most promising revenue locus remains premium revenue at 10.17 billion US dollars last quarter-equivalent run-rate, where a stabilizing redetermination cadence and rate adjustments could support sequential normalization; year-over-year growth for the current quarter is expected to contract 1.56% at the consolidated level.
Last Quarter Review
Molina Healthcare’s previous quarter delivered revenue of 10.80 billion US dollars, a gross margin of 9.93%, GAAP net income attributable to shareholders of 14.00 million US dollars with a net margin of 0.14%, and adjusted EPS of 2.35, with year-over-year changes of -3.15% for revenue and -61.35% for adjusted EPS.
A key feature of the quarter was a sharp quarter-on-quarter rebound in parent net income, with the metric rising 108.75%, reflecting improved claims development versus the prior period’s pressure. The main business remained anchored by premiums at 10.17 billion US dollars, insurance premium taxes at 0.50 billion US dollars, and investment income at 0.10 billion US dollars; consolidated revenue declined 3.15% year over year.
Current Quarter Outlook
Main business: Medicaid and managed care premium revenue trajectory
The current-quarter setup revolves around the premium revenue base, which historically represents more than nine-tenths of consolidated revenue. With revenue modeled at 10.78 billion US dollars and the consolidated year-over-year change at -1.56%, the implied premium trajectory reflects a blend of ongoing Medicaid redeterminations and state-rate true-ups. Medical cost trend visibility is essential: any deviation in seasonality, mix shift from higher-acuity cohorts, or utilization normalization in behavioral and pharmacy could influence the medical loss ratio and hence gross margin. Given that last quarter’s gross margin was 9.93% and net margin 0.14%, even modest improvements in utilization or pharmacy rebates could have an outsized effect on incremental earnings given the tight margin structure.
Most promising business: Premium revenue stabilization via rate actions and membership mix
The segment with the clearest path to improving contribution remains premiums, which comprised 10.17 billion US dollars in the last quarter and continues to benefit from state-level rate adjustments and contract renewals. The constructive case centers on a plateauing of Medicaid redetermination-linked disenrollments and the capture of higher-acuity members at adequate rates, which can translate to incremental gross margin expansion from a low base. Additionally, improving investment income can cushion periods of elevated medical costs, while administrative expense leverage could support operating margins if revenue holds near the 10–11 billion US dollars band.
Key stock-price drivers this quarter: Medical cost trend, redeterminations cadence, and operating leverage
Three variables are likely to set the tone for share performance around earnings. The first is the medical cost trend, especially inpatient, behavioral health, and specialty pharmacy claims; a modest undershoot versus internal accruals would flow through to EBIT and EPS given the low current net margin. The second is the cadence of Medicaid redeterminations and related membership updates; evidence of stabilization or favorable mix can mitigate revenue pressure and support future rate filings. The third is operating leverage, particularly G&A efficiency; if management demonstrates cost discipline while maintaining service levels, EBIT could outperform the 0.14 billion US dollars forecast even if revenue is modestly below plan.
Analyst Opinions
Institutional commentary in the period points to a cautious tilt, with a majority emphasizing earnings vulnerability tied to medical cost normalization and lingering enrollment headwinds; views generally frame downside risk to EPS relative to historical run-rates rather than to the current low consensus baseline. Noted sell-side voices highlight that the modeled EPS of about 1.39 embeds a large year-over-year decline of roughly 75.98%, implying that any adverse cost variance could still lead to modest misses, whereas favorable utilization could generate positive surprises from a compressed starting point. The same cohort underscores that premium revenue concentration near 94% heightens sensitivity to MLR outcomes and state-rate timing, keeping sentiment balanced but guarded into July 22, 2026 Post-Mkt.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments